Projects per year
Personal profile
Biography
Jennifer Hoy has over 30 years experience in HIV clinical research and patient care. She is the inaugural Professor Director of HIV Medicine at the Alfred Hospital and Monash University, Melbourne and established the Infectious Diseases Clinical Research Unit at Fairfield Hospital prior to its move to The Alfred Hospital.
Professor Hoy has made significant contributions to the HIV research effort nationally and internationally. She has been Principal Investigator (PI) for over 200 clinical studies at the Alfred Hospital (Fairfeld Hospital) and has collaborated widely on investigator-initiated pathogenesis studies. Her main research interest is in the evaluation of the causes of co-morbidity and mortality in people living with HIV infection and the effect of Antiretroviral Therapy. Her current research interests include the comorbidities associated with Aging and HIV, in particular bone disease and cardiovascular disease, and the impact of residual immune activation and chronic inflammation. Her other passion is ensuring the quality of care provided to PLHIV, and quality of life experienced by PLHIV.
She has mentored over 10 postgraduate students (MPH, PhD, postdoctoral fellows). Her research productivity is evidenced by over 200 peer-reviewed publications, and the editing/authorship of 8 books. She was a member of the Australian Antiretroviral Guidelines Panel for over 10 years, and has been a productive member of the international IAS-USA Antiretroviral Guidelines panel since 2012.
Research interests
HIV and Bone Disease
People living with HIV (PLHIV) have lower bone mineral density (BMD) and experience more fractures than the general population of similar age. Both HIV-infection and antiretroviral treatment (ART) for HIV contribute to BMD loss, along with traditional risk factors; the relative contributions of lifestyle factors, HIV and ART are unknown.
The effect of HIV alone and introduction of ART was evaluated in 400 patients in the START study (START BMD substudy) and revealed that initiation of ART results in greater declines in bone mineral density than deferring ART and declines were greatest in the first year of ART. No clinical, HIV-related, or ART characteristics predicted greater BMD loss.
Significant ART-induced bone loss slows after the first year of ART.
It is known that all ART drugs can increase BMD loss in HIV patients, but exposure to tenofovir disoproxil fumarate appears to have a significantly greater effect. In patients with low BMD, it was unknown whether switching tenofovir DF to another ART drug or treatment with a bisphosphonate is the more effective and safe option for increasing bone mineral density. A randomised trial (ZeST study) has now demonstrated that treatment with zoledronic acid was superior to switching the tenofovir DF.
Stored samples are available from these studies to further understand the role of ART in loss of bone.
HIV and Cardiovascular Diseases
Cardiovascular disease is one of the major causes of morbidity and mortality in people living with HIV, with a 2-fold increased risk when compared with the general population.
This elevated risk is likely due to a complex interplay between the increased incidence of traditional cardiac risk factors, the adverse effects of ART and the pro-inflammatory effects of HIV itself.
A number of projects are being undertaken to better understand the contributions of lipid abnormalities, chronic inflammation and platelet function in the observed increased risk of atherosclerosis and clinical CVD events.
Access to the Victorian HIV Service database which contains clinical and treatment characteristics of people who received HIV care through Fairfield Hospital/Alfred Hospital and a plasma sample repository (Victorian HIV Blood and Tissue Storage Bank) following Research and Ethics approval, underpins the research into HIV and comorbidities.
Clinical activities
Director of HIV Medicine, The Alfred
Prof Hoy has over 30 years’ experience in HIV clinical research and patient care, and established the Clinical Research Unit at The Alfred. Prior to this, she established and directed the Infectious Diseases Clinical Research Unit from 1988-2008, building it into an internationally recognized research program.
She has been Principal Investigator for over 175 clinical studies at The Alfred and has collaborated widely on investigator-initiated pathogenesis studies.
Consulting
1997 Rescriptor Focus Group (Pharmacia and Upjohn, Sydney
1997 Roche HIV Advisory Board, Sydney
2004-2007 Roche Enfuvirtide Advisory Board
2001-2023 Gilead Advisory Board
2002-2007 Bristol Myers Squibb Advisory Board
2004-2007 Boehringer-Ingelheim HIV Panel Discussion Group
2005-2006 Abbott Kaletra Advisory Board
2005-2018 Merck Sharp & Dohme Advisory Board
2005-2013 Janssen-Cilag Australia HIV Advisory Board
2006-2007 Pfizer Maraviroc Advisory Board
2007-2017 International Gilead Advisory Board
2009-2023 ViiV Advisory Board
2017-2018 ViiV Global D3 Advisory Board
Community service
Community Teaching
- Education and Resource Centre, The Alfred Hospital 2008-2017
- When to Start ART, 2016
- National Association of People Living with HIV/AIDS 2009-2013
- Basic Science of HIV presentation – NAPWHA – March 2013
- Victorian HIV Service Now and in the Future – 2015 presentations to Victorian AIDS Council Board, and Living Positive Board
- Pheonix program – Living Positive Victoria, Straight Arrows and Poz Women 2016-2023
- HIV and Ageing – THH and Living Positive Victoria 2020-22
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Education/Academic qualification
Medicine, Graduate Diploma in Epidemiology and Biostatistics, University of Melbourne
Award Date: 1 Dec 1995
Medicine, M.B.B.S., MONASH UNIVERSITY
Award Date: 1 Dec 1977
External positions
Director HIV Medicine, Alfred Hospital
1 Oct 2007 → …
Honorary Senior Principal Research Fellow, Burnet Institute (Australia)
Director, Victorian HIV Service
Research area keywords
- HIV/AIDS
- Infectious Diseases
- Aging
- Osteoporosis
- Cardiovascular disease
Collaborations and top research areas from the last five years
-
Improving the Long-term Health in People Living with HIV: The RESPOND Study
Petoumenos, K. (Primary Chief Investigator (PCI)), Law, M. G. (Chief Investigator (CI)), Hoy, J. (Chief Investigator (CI)), Carr, A. D. (Chief Investigator (CI)), Bloch, M. T. (Chief Investigator (CI)), Boettiger, D. C. (Chief Investigator (CI)), Dharan, N. (Chief Investigator (CI)) & Barbieri, S. (Chief Investigator (CI))
1/07/23 → 30/06/27
Project: Research
-
How to target monocyte/macrophage reservoirs as part of a functional cure for HIV
Jaworowski, A. (Primary Chief Investigator (PCI)), Hearps, A. (Chief Investigator (CI)) & Hoy, J. (Chief Investigator (CI))
1/01/20 → 31/12/21
Project: Research
-
Ensuring HIV positive people are retained in care: establishing clinical pathways for retention
Peleg, A. (Primary Chief Investigator (PCI)), McMahon, J. (Chief Investigator (CI)), Hoy, J. (Chief Investigator (CI)), Stoove, M. (Chief Investigator (CI)), El-Hayek, C. (Chief Investigator (CI)), Eu, B. (Chief Investigator (CI)), Tee, B. K. (Chief Investigator (CI)), Woolley, I. (Chief Investigator (CI)) & Street, A. (Chief Investigator (CI))
22/12/17 → 31/12/18
Project: Research
-
Risk factors for long-term chronic disease events in HIV-positive persons: the D:A:D cohort study
Law, M. G. (Primary Chief Investigator (PCI)), Petoumenos, K. (Chief Investigator (CI)), Carr, A. D. (Chief Investigator (CI)), Hoy, J. (Chief Investigator (CI)) & Nolan, D. (Chief Investigator (CI))
1/01/17 → 31/12/21
Project: Research
-
A new monocyte atherogenic phenotype in chronic HIV disease.
Jaworowski, A. (Primary Chief Investigator (PCI)), Hoy, J. (Chief Investigator (CI)), Crowe, S. (Chief Investigator (CI)), Elliott, J. (Chief Investigator (CI)) & Hearps, A. (Chief Investigator (CI))
1/01/16 → 31/12/18
Project: Other
-
Deconvoluting the contribution of antiretroviral choice in weight gain
Nicol, M. R., Dawood, H. & Hoy, J. F., 1 Oct 2024, In: AIDS. 38, 12, p. 1794-1795 2 p.Research output: Contribution to journal › Comment / Debate › Other › peer-review
-
Is this the end of the road for daily islatravir 0·75 mg?
Hoy, J. & McMahon, J., Jun 2024, In: The Lancet HIV. 11, 6, p. e346-e347 2 p.Research output: Contribution to journal › Comment / Debate › Other › peer-review
2 Citations (Scopus) -
Agreements, Behaviour, and Change: Sex Outside the Relationship in Male HIV-negative Partners in HIV Serodiscordant Relationships in Australia, Brazil, and Thailand
Gray, J., Prestage, G., Jin, F., Phanuphak, N., Friedman, R. K., Fairley, C. K., Kelleher, A., Templeton, D. J., Zablotska-Manos, I., Hoy, J., McNulty, A., Baker, D., Brown, G., Grulich, A., Bavinton, B. & for the Opposites Attract study group, Sept 2023, In: AIDS and Behavior. 27, 9, p. 3098-3108 11 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access -
Antiretroviral Drugs for Treatment and Prevention of HIV Infection in Adults: 2022 Recommendations of the International Antiviral Society-USA Panel
Gandhi, R. T., Bedimo, R., Hoy, J. F., Landovitz, R. J., Smith, D. M., Eaton, E. F., Lehmann, C., Springer, S. A., Sax, P. E., Thompson, M. A., Benson, C. A., Buchbinder, S. P., Del Rio, C., Eron, J. J., Günthard, H. F., Molina, J. M., Jacobsen, D. M. & Saag, M. S., 3 Jan 2023, In: JAMA. 329, 1, p. 63-84 22 p.Research output: Contribution to journal › Article › Research › peer-review
Open Access379 Citations (Scopus) -
Asymptomatic people with well-controlled HIV do not have abnormal left ventricular global longitudinal strain
Hoy, J. F., Lee, S. J., Trevillyan, J. M., Dewar, E. M., Roney, J., Dart, A. & Yang, Y., 2023, In: Frontiers in Cardiovascular Medicine. 10, 9 p., 1198387.Research output: Contribution to journal › Article › Research › peer-review
Open Access
Prizes
-
Allen Yung Award for Excellence in Infectious Diseases Teaching in Victoria
Hoy, J. (Recipient), 2017
Prize: Prize (including medals and awards)
-
Fellow Australian Academy of Health and Medical Sciences
Hoy, J. (Recipient), 2019
Prize: Election to learned society
-
-
-
Activities
-
Asia Pacific AIDS and Co-infections Conference (APACC)
Hoy, J. (Keynote/plenary speaker)
2023Activity: Participating in or organising an event types › Contribution to conference
-
HIV Cascade of Care: Closing the Gap
Hoy, J. (Keynote/plenary speaker)
2023Activity: Participating in or organising an event types › Contribution to conference
-
Asia Pacific AIDS and Co-infections Conference (APACC)
Hoy, J. (Keynote/plenary speaker)
2022Activity: Participating in or organising an event types › Contribution to conference
-
International Society for Infectious Diseases
Hoy, J. (Invited speaker)
2022Activity: Participating in or organising an event types › Contribution to conference
-
Annual Scientific meeting of the Australasian Society for Infectious Diseases 2021
Hoy, J. (Keynote/plenary speaker)
24 Mar 2021Activity: Participating in or organising an event types › Contribution to conference
Press/Media
-
COVID vaccinations for People with HIV
6/07/21
1 Media contribution
Press/Media: Public Engagement Activities
-
-
Could It Be HIV?
29/11/17
1 Media contribution
Press/Media: Blogs, Podcasts and Social Media › Podcasts